RECRUITING

Redefining BMI: The Body, Mind, and Inflammation Trial

Description

Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.

Conditions

ObesityAdiposity
Talk to us

Related Conditions:

ObesityAdiposity

Study Overview

On this page

Study Details

Study overview

Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.

Redefining BMI: The Body, Mind, and Inflammation Trial

Redefining BMI: The Body, Mind, and Inflammation Trial

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Richmond

Virginia Commonwealth Universtity, Richmond, Virginia, United States, 23298

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ages 18-25 years
  • * Body mass index (BMI) 25-50 kg/m\^2
  • * Female
  • * Currently pregnant or lactating
  • * Current involvement in a weight loss program or current use of weight loss medication
  • * Lost \>5% of their body weight in the previous 3 months
  • * Uncontrolled medical conditions that may pose a safety issue given the recommendations for the diet and unsupervised physical activity
  • * Diagnosis of type 2 diabetes and/or impaired fasting blood glucose
  • * Diagnosis of type 1 diabetes
  • * Rheumatologic and gastrointestinal conditions associated with severe systemic inflammation
  • * Medical conditions resulting in known perturbations in the hypothalamic-pituitary-adrenal axis
  • * Report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness
  • * Current or recent (during the past 3 months) use of medications that may impact weight or metabolic function
  • * Current or recent (during the past 3 months) use of anti-inflammatory medications
  • * Report of diagnosis or history of Anorexia Nervosa or Bulimia Nervosa, or any compensatory behaviors within the previous 3 months
  • * Hospitalization for depression or other psychiatric disorder within the past 12 months
  • * Uncontrolled bipolar disorder or psychotic disorder
  • * Current suicidal intent
  • * Planning to move from the area within the study period
  • * Unwilling to be randomized to either study condition
  • * Unable to read and speak English

Ages Eligible for Study

18 Years to 25 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Virginia Commonwealth University,

Jessica LaRose, PRINCIPAL_INVESTIGATOR, Virginia Commonwealth University

Study Record Dates

2026-04